- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01215500
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
A Study of Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
Patients with metastatic cancer are generally treated with chemotherapy, which has improved median survival compared to best supportive care. Despite this, patients continue to have persistent disease at sites that were initially involved with cancer. Radiation therapy is an effective modality for treating localized cancer but generally has been only used for palliation of symptoms once a patient develops metastatic disease. Since patients often have persistent disease after chemotherapy, the goal of this trial is to use increasing doses of radiation therapy to all sites of involved disease in order to determine the safety and efficacy of hypofractionated radiation therapy.
The purpose of this study is to establish a maximum tolerated dose, dose-limiting toxicities, and recommended phase 2 dose of hypofractionated radiation therapy.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- University of Chicago
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of cancer (including epithelial carcinoma, sarcoma, and melanoma)
- Age 18 years and older
- Life expectancy of > 3 months
- Patients with AJCC (6th edition, 2002) stage IV cancer with distant metastases and without pleural or pericardial effusion at diagnosis and before start of study
- Patients with 1-5 sites of maximum tumor dimension (for each individual site) of ≤ 10 cm or < 500 cc volume and amenable to radiation therapy as seen on standard imaging
- Unidimensionally measurable disease (based on RECIST) is desirable but not strictly required
- Brain metastases must have been treated prior to enrollment on study, preferably with stereotactic radiosurgery
- ECOG performance status ≤ 2 or Karnofsky Performance Status ≥ 60%
- No prior radiation therapy to currently involved tumor sites
- Room air saturation > 90%
- Hemoglobin > 9.0 g/dl
- ANC >=1,500/microliter
- Platelets >=100,000/microliter
- Total bilirubin within institutional limits
- Albumin > 2.9 g/dl
- Alkaline phosphatase < 2.5x upper limit of normal
- AST and ALT < 2.5 x upper limit of normal
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Uncontrolled intercurrent illness
- Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. Exclusion of patients with active coronary heart disease will be at the discretion of the attending physician
- Patients with significant atelectasis such that CT definition of gross tumor volume is difficult to determine
- Pregnancy or breast feeding
- Patients must have no uncontrolled active infection other than that not curable with treatment of their cancer.
- Patients may not be receiving any other investigational drugs during RT
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Strålbehandling
|
RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy: For all sites the dose levels are as follows:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Dose-limiting toxicities
Tidsram: 30-90 days
|
The dose limiting toxicities occurring within the initial observation period will be defined.
|
30-90 days
|
maximum tolerated dose of hypofractionated RT
Tidsram: 30-90 days
|
30-90 days
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 13619B
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Melanom
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RekryteringMetastaserande melanom | Konjunktivalt melanom | Okulärt melanom | Ooperabelt melanom | Uveal melanom | Kutant melanom | Slemhinnemelanom | Iris melanom | Akralt melanom | Icke-kutant melanomFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Steg IIB melanom | Steg IIC melanom | Steg IA melanom | Steg IB melanom | Steg IIA melanomFörenta staterna
-
MelanomaPRO, RussiaRekryteringMelanom | Melanom (hud) | Melanom Steg IV | Melanom stadium III | Melanom, stadium II | Melanom, Uveal | Melanom in Situ | Melanom, OkulärRyska Federationen
-
University of Southern CaliforniaNational Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Slemhinnemelanom | Ciliary Body och Choroid Melanom, Medium/Large Storlek | Ciliarkropp och koroid melanom, liten storlek | Iris melanom | Metastaserande intraokulärt melanom | Återkommande intraokulärt melanom | Steg IV Intraokulärt melanom | Steg IIIA melanom | Steg... och andra villkorFörenta staterna
-
BiocadRekryteringMelanom | Melanom (hud) | Melanom Steg IV | Melanom stadium III | Melanom Metastaserande | Melanom ooperabelt | Melanom AvanceratIndien, Ryska Federationen, Belarus
-
Mayo ClinicNational Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Steg IIB melanom | Steg IIC melanom | Steg IIA melanomFörenta staterna
-
National Cancer Institute (NCI)AvslutadSteg IV melanom | Ciliary Body och Choroid Melanom, Medium/Large Storlek | Iris melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Extraokulärt förlängningsmelanom | Steg IIB melanom | Steg IIC melanomFörenta staterna
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkAvslutadÅterkommande melanom | Steg IV melanom | Metastaserande intraokulärt melanom | Återkommande intraokulärt melanom | Steg IV Intraokulärt melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Extraokulärt förlängningsmelanom | Steg IIIA Intraokulärt melanom | Steg IIIB Intraokulärt melanom | Steg...Förenta staterna
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RekryteringOoperabelt melanom | Kliniskt stadium III kutant melanom AJCC v8 | Melanom hos okänd primär | Patologiskt stadium IIIB kutant melanom AJCC v8 | Patologiskt stadium IIIC kutant melanom AJCC v8 | Patologiskt stadium IIID kutant melanom AJCC v8 | Kliniskt stadium IV kutant melanom AJCC v8 | Patologiskt... och andra villkorFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Akralt lentiginöst malignt melanomFörenta staterna
Kliniska prövningar på Hypofractionated RT
-
Institut Català d'OncologiaRekrytering
-
Groupe Oncologie Radiotherapie Tete et CouGustave Roussy, Cancer Campus, Grand ParisAvslutadSkivepitelcancer i huvud och nackeFrankrike, Monaco
-
The Netherlands Cancer InstituteM.D. Anderson Cancer Center; Mayo Clinic; Radboud University Medical Center; Aarhus University Hospital och andra samarbetspartnersRekryteringMyxoid liposarkomNederländerna
-
Children's Hospital Medical Center, CincinnatiRekryteringAutismspektrumstörning | KänsloregleringFörenta staterna
-
Karolinska InstitutetThe Swedish Research Council; Swedish Cancer SocietyAvslutad
-
Moai Technologies LLCSt. Louis University; University of Texas-ArlingtonRekryteringDemensFörenta staterna
-
Cristian AlvarezUniversidad de La FronteraAvslutad
-
Medical College of WisconsinRekrytering
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaAvslutadBröstcancer | Strålningstoxicitet
-
Postgraduate Institute of Medical Education and...RekryteringBröstcancer | Strålbehandlingsbiverkning | HypofraktioneringIndien